Literature DB >> 9316901

Are clinical laboratories in California accurately reporting vancomycin-resistant enterococci?

J Rosenberg1, F C Tenover, J Wong, W Jarvis, D J Vugia.   

Abstract

In order to determine whether hospital-based clinical laboratories conducting active surveillance for vancomycin-resistant enterococci in three San Francisco Bay area counties (San Francisco, Alameda, and Contra Costa counties) were accurately reporting vancomycin resistance, five vancomycin-resistant enterococcal strains and one vancomycin-susceptible beta-lactamase-producing enterococcus were sent to 31 of 32 (97%) laboratories conducting surveillance. Each strain was tested by the laboratory's routine antimicrobial susceptibility testing method. An Enterococcus faecium strain with high-level resistance to vancomycin (MIC, 512 microg/ml) was correctly reported as resistant by 100% of laboratories; an E. faecium strain with moderate-level resistance (MIC, 64 microg/ml) was correctly reported as resistant by 91% of laboratories; two Enterococcus faecalis strains with low-level resistance (MICs, 32 microg/ml) were correctly reported as resistant by 97 and 56% of laboratories, respectively. An Enterococcus gallinarum strain with intrinsic low-level resistance (MIC, 8 microg/ml) was correctly reported as intermediate by 50% of laboratories. A beta-lactamase-producing E. faecalis isolate was correctly identified as susceptible to vancomycin by 100% of laboratories and as resistant to penicillin and ampicillin by 68 and 44% of laboratories, respectively; all 23 (74%) laboratories that tested for beta-lactamase recognized that it was a beta-lactamase producer. This survey indicated that for clinically significant enterococcal isolates, laboratories in the San Francisco Bay area have problems in detecting low- to moderate-level but not high-level vancomycin resistance. Increasing accuracy of detection and prompt reporting of these isolates and investigation of cases are the next steps in the battle for control of the spread of vancomycin resistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316901      PMCID: PMC230004          DOI: 10.1128/jcm.35.10.2526-2530.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  In vitro detection of enterococcal vancomycin resistance.

Authors:  D F Sahm; L Olsen
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

2.  A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit.

Authors:  L V Karanfil; M Murphy; A Josephson; R Gaynes; L Mandel; B C Hill; J M Swenson
Journal:  Infect Control Hosp Epidemiol       Date:  1992-04       Impact factor: 3.254

3.  One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin.

Authors:  R Williamson; C le Bouguénec; L Gutmann; T Horaud
Journal:  J Gen Microbiol       Date:  1985-08

Review 4.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

5.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

6.  Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism.

Authors:  D J Krogstad; T R Korfhagen; R C Moellering; C Wennersten; M N Swartz
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

7.  Revised approach for identification and detection of ampicillin and vancomycin resistance in Enterococcus species by using MicroScan panels.

Authors:  P C Iwen; D M Kelly; J Linder; S H Hinrichs
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

8.  Detection of vancomycin resistance in Enterococcus species.

Authors:  B M Willey; B N Kreiswirth; A E Simor; G Willaims; S R Scriver; A Phillips; D E Low
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

9.  Vancomycin-resistant Enterococcus faecium in hospitalized children.

Authors:  L G Rubin; V Tucci; E Cercenado; G Eliopoulos; H D Isenberg
Journal:  Infect Control Hosp Epidemiol       Date:  1992-12       Impact factor: 3.254

10.  Recovery of resistant enterococci during vancomycin prophylaxis.

Authors:  A H Kaplan; P H Gilligan; R R Facklam
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

View more
  6 in total

Review 1.  The role of DNA amplification technology in the diagnosis of infectious diseases.

Authors:  M Louie; L Louie; A E Simor
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

2.  Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci.

Authors:  Y S Chen; S A Marshall; P L Winokur; S L Coffman; W W Wilke; P R Murray; C A Spiegel; M A Pfaller; G V Doern; R N Jones
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

3.  Use of the National Committee for Clinical Laboratory Standards guidelines for disk diffusion susceptibility testing in New York state laboratories.

Authors:  J A Kiehlbauch; G E Hannett; M Salfinger; W Archinal; C Monserrat; C Carlyn
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

4.  Use of tests for acidification of methyl-alpha-D-glucopyranoside and susceptibility to efrotomycin for differentiation of strains of Enterococcus and some related genera.

Authors:  M G Carvalho; L M Teixeira; R R Facklam
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

5.  Proficiency in detecting vancomycin resistance in enterococci among clinical laboratories in Santiago, Chile.

Authors:  J A Labarca; L C McDonald; M E Pinto; E Palavecino; P González; E Cona; A Fernández; M S Giglio; W R Jarvis
Journal:  Emerg Infect Dis       Date:  1999 Nov-Dec       Impact factor: 6.883

6.  Proficiency of clinical laboratories in and near Monterrey, Mexico, to detect vancomycin-resistant enterococci.

Authors:  L C McDonald; L R Garza; W R Jarvis
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.